Radiopharmaceutical company Lantheus Holdings (NASDAQ: LNTH) will be announcing earnings results tomorrow before market open. Here’s what you need to know.
Lantheus beat analysts’ revenue expectations by 3.8% last quarter, reporting revenues of $391.1 million, up 10.5% year on year. It was a mixed quarter for the company, with a decent beat of analysts’ full-year EPS guidance estimates.
Is Lantheus a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Lantheus’s revenue to grow 2.4% year on year to $378.8 million, slowing from the 23% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.65 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lantheus has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Lantheus’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 2.8%, beating analysts’ expectations by 2.5%, and Hologic reported a revenue decline of 1.2%, in line with consensus estimates. GE HealthCare’s stock price was unchanged after the results, while Hologic was down 5.4%.
Read our full analysis of GE HealthCare’s results here and Hologic’s results here.
There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 4.4% on average over the last month. Lantheus is up 13.1% during the same time and is heading into earnings with an average analyst price target of $134.92 (compared to the current share price of $107.98).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
